Characteristics of myeloid sarcoma in mice and patients with TET2 deficiency. Corrigendum in /10.3892/ol.2020.11907

Wang,Jinhuan; Miao,Zhaoyi; Jiang,Yanan; Zou,Ping; Li,Weiming; Tang,Xiaoqiong; Lv,Yangyang; Xing,Donghui; Chen,Shi; Yang,Fengchun; Xu,Mingjiang; Cao,Zeng; Wang,Haitao; Zhao,Zhigang

doi:10.3892/ol.2020.11479

Characteristics of myeloid sarcoma in mice and patients with TET2 deficiency.

Corrigendum in: /10.3892/ol.2020.11907

Authors:
- Jinhuan Wang
- Zhaoyi Miao
- Yanan Jiang
- Ping Zou
- Weiming Li
- Xiaoqiong Tang
- Yangyang Lv
- Donghui Xing
- Shi Chen
- Fengchun Yang
- Mingjiang Xu
- Zeng Cao
- Haitao Wang
- Zhigang Zhao
View Affiliations

Affiliations: Department of Oncology, Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China, Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, P.R. China, Department of Hematology, The Union Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China, Sylvester Comprehensive Cancer Center, Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
Published online on: March 27, 2020 https://doi.org/10.3892/ol.2020.11479
Pages: 3789-3798
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Myeloid sarcoma (MS) carries a poor prognosis, and information on epigenetic modifications in MS is currently limited. In the present study, 214 ten-eleven translocation‑2 (TET2)‑/‑ mice were successfully constructed. In addition, 436 patients with myelodysplastic syndrome (MDS) and 354 with acute myeloid leukemia (AML) patients were recruited. The incidence of MS in mice and patients with TET2 deficiency was examined, and the efficiency of hypomethylating agents (HMAs) was also be evaluated. A total of 93% of the TET2‑/‑ mice developed myeloid malignancies, 5.5% of which were accompanied by MS (n=11). The survival of these TET2‑/‑ mice ranged between 3 and 25 months. No significant difference was observed between the survival of MS and non‑MS mice with TET2 loss (P>0.05). In addition, MS cells were transplantable, and their recipients exhibited myeloproliferative characteristics, such as increased white blood cell counts, monocytosis, low erythrocyte counts and hepatosplenomegaly. Their median survival duration was 94.8 days. In the clinical setting, 9.7% of MDS and 11.6% of AML patients with TET2 deficiency developed MS, which was higher compared with previous reports (1.5‑9.1%). The median age of the MS patients was 44 years old. 5‑Aza‑2'‑deoxycytidine (5‑Aza‑dC) reduced the incidence of MS in TET2‑/‑ mice, and decitabine was a suitable treatment strategy for MS patients. These data indicate that TET2 deficiency plays a key role in MS and its prognostic significance requires further investigation. HMAs may be a useful treatment for MS patients with TET2 mutations.

View Figures

View References

1	Byrd JC, Edenfield WJ, Shields DJ and Dawson NA: Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: A clinical review. J Clin Oncol. 13:1800–1816. 1995. View Article : Google Scholar : PubMed/NCBI
2	Liu PI, Ishimaru T, McGregor DH, Okada H and Steer A: Autopsy study of granulocytic sarcoma (chloroma) in patients with myelogenous leukemia, Hiroshima-Nagasaki 1949–1969. Cancer. 31:948–955. 1973. View Article : Google Scholar : PubMed/NCBI
3	Neiman RS, Barcos M, Berard C, Bonner H, Mann R, Rydell RE and Bennett JM: Granulocytic sarcoma: A clinicopathologic study of 61 biopsied cases. Cancer. 48:1426–1437. 1981. View Article : Google Scholar : PubMed/NCBI
4	Wiernik PH and Serpick AA: Granulocytic sarcoma (chloroma). Blood. 35:361–369. 1970. View Article : Google Scholar : PubMed/NCBI
5	Krause JR: Granulocytic sarcoma preceding acute leukemia: A report of six cases. Cancer. 44:1017–1021. 1979. View Article : Google Scholar : PubMed/NCBI
6	Issa JP: The myelodysplastic syndrome as a prototypical epigenetic disease. Blood. 121:3811–3817. 2013. View Article : Google Scholar : PubMed/NCBI
7	Mohammadiasl J, Khosravi A, Shahjahani M, Azizidoost S and Saki N: Molecular and cellular aspects of extramedullary manifestations of acute myeloid leukemia. J Cancer Metastasis Treat. 2:44–50. 2016.
8	Ohanian M, Faderl S, Ravandi F, Pemmaraju N, Garcia-Manero G, Cortes J and Estrov Z: Is acute myeloid leukemia a liquid tumor? Int J Cancer. 133:534–543. 2013. View Article : Google Scholar : PubMed/NCBI
9	Tallman MS, Hakimian D, Shaw JM, Lissner GS, Russell EJ and Variakojis D: Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. J Clin Oncol. 11:690–697. 1993. View Article : Google Scholar : PubMed/NCBI
10	Sugimoto Y, Nishii K, Sakakura M, Araki H, Usui E, Lorenzo VF, Hoshino N, Miyashita H, Ohishi K, Katayama N and Shiku H: Acute myeloid leukemia with t(8;21)(q22;q22) manifesting as granulocytic sarcomas in the rhinopharynx and external acoustic meatus at relapse after high-dose cytarabine: Case report and review of the literature. Hematol J. 5:84–89. 2004. View Article : Google Scholar : PubMed/NCBI
11	Jiang L, Yu G, Meng W, Wang Z, Meng F and Ma W: Overexpression of amyloid precursor protein in acute myeloid leukemia enhances extramedullary infltration by MMP-2. Tumour Biol. 34:629–636. 2013. View Article : Google Scholar : PubMed/NCBI
12	Mirza MK, Sukhanova M, Stölzel F, Onel K, Larson RA, Stock W, Ehninger G, Kuithan F, Zöphel K, Reddy P, et al: Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: Characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays. Leuk Res. 38:1091–1096. 2014. View Article : Google Scholar : PubMed/NCBI
13	Riddle A and Olsen B: Erythroblastic sarcoma. Leuk Res. 36:e182–e184. 2012. View Article : Google Scholar : PubMed/NCBI
14	Chang H, Brandwein J, Yi QL, Chun K, Patterson B and Brien B: Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leuk Res. 28:1007–1011. 2004. View Article : Google Scholar : PubMed/NCBI
15	Curran MP: Decitabine: A review of its use in older patients with acute myeloid leukaemia. Drugs Aging. 30:447–458. 2013. View Article : Google Scholar : PubMed/NCBI
16	Delatte B, Deplus R and Fuks F: Playing TETris with DNA modifcations. EMBO J. 33:1198–1211. 2014. View Article : Google Scholar : PubMed/NCBI
17	Solary E, Bernard OA, Tefferi A, Fuks F and Vainchenker W: The ten-eleven translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia. 28:485–496. 2014. View Article : Google Scholar : PubMed/NCBI
18	Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM, Hanson CA, Pardanani A, Gilliland DG and Levine RL: Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia. 23:1343–1345. 2009. View Article : Google Scholar : PubMed/NCBI
19	Pan Y, Tao Y, Fu C, Jia J, Liu S and Xiao D: Assessment of PET/CT in multifocal myeloid sarcomas with loss of TET2: A case report and literature review. Int J Clin Exp Pathol. 8:13630–13634. 2015.PubMed/NCBI
20	Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, et al: Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 468:839–843. 2010. View Article : Google Scholar : PubMed/NCBI
21	Li Z, Cai X, Cai CL, Wang J, Zhang W, Petersen BE, Yang FC and Xu M: Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood. 118:4509–4518. 2011. View Article : Google Scholar : PubMed/NCBI
22	Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405. 2016. View Article : Google Scholar : PubMed/NCBI
23	Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, et al: International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 108:1497–1503. 2006. View Article : Google Scholar : PubMed/NCBI
24	Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and Rubin P: CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 13:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
25	Morse HC III, Anver MR, Fredrickson TN, Haines DC, Harris AW, Harris NL, Jaffe ES, Kogan SC, MacLennan IC, Pattengale PK, et al: Bethesda proposals for classification of lymphoid neoplasms in mice. Blood. 100:246–258. 2002. View Article : Google Scholar : PubMed/NCBI
26	Kogan SC, Ward JM, Anver MR, Berman JJ, Brayton C, Cardiff RD, Carter JS, de Coronado S, Downing JR, Fredrickson TN, et al: Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood. 100:238–245. 2002. View Article : Google Scholar : PubMed/NCBI
27	Pan F, Wingo TS, Zhao Z, Gao R, Makishima H, Qu G, Lin L, Yu M, Ortega JR, Wang J, et al: Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. Nat Commun. 8:151022017. View Article : Google Scholar : PubMed/NCBI
28	Evers D, Bär BMAM, Gotthardt M and van der Velden WJFM: Activity of decitabine in pericardial myeloid sarcoma. Int J Hematol. 108:121–122. 2018. View Article : Google Scholar : PubMed/NCBI
29	Gornicec M, Wölfler A, Stanzel S, Sill H and Zebisch A: Evidence for a role of decitabine in the treatment of myeloid sarcoma. Ann Hematol. 96:505–506. 2017. View Article : Google Scholar : PubMed/NCBI
30	Zhang XH, Zhang R and Li Y: Granulocytic sarcoma of abdomen in acute myeloid leukemia patient with inv(16) and t(6;17) abnormal chromosome: Case report and review of literature. Leuk Res. 34:958–961. 2010. View Article : Google Scholar : PubMed/NCBI